The International Liver Conference 2015
At the 2015 International Liver Congress, "scientific and medical experts from a broad range of fields including hepatology, gastroenterology, internal medicine, cell biology, transplant surgery, infectious diseases, microbiology and virology, pharmacology, pathology, radiology and imaging, come together from around the world to learn about the latest in liver research."
Georgios Grammatikos, MD, commented at The International Liver Congress 2015 in Vienna, Austria, "We do think in liver diseases we show the opening of this topic in chronic hepatopathy and we do believe mass spectrometric methods -- in order to identify the levels of single lipids-- as one method of the future."
Video Interview: Vinood Patel, PhD, PGCHE, fHEA, FRSC, University of Westminster, London, UK, discussed his hope for hepatologists to better understand the mechanisms that lead from fatty liver to steatohepatitis and subsequently from steatohepatitis to cirrhosis at The International Liver Congress 2015.
The use of interferon to treat hepatitis C infections has fallen out of favor with the advent of new antivirals and drug combinations that have fewer side effects. But in a study presented at the 2015 International Liver Congress in Vienna, Austria, researchers from the UK said that physicians should put interferon back on the treatment menu.
When it comes to developing heart disease, patients who have non-alcoholic steatohepatitis (NASH) liver disease are at greater risk of both cardiovascular illness and death than patients with non-alcoholic fatty liver disease a UK team reported today at the International Liver Congress in Vienna, Austria.
So far there are no approved pharmaceuticals for treating a common liver disease, non-alcoholic steatohepatitis (NASH). But in a second encouraging drug development reported at the International Liver Congress in Vienna, Austria this morning, Austria, researchers said they like what they see in a trial of Liraglutide (Saxenda/ NovoNordisk).
Patients with severe cirrhosis, those who are waiting for a liver transplant, or have recurrent hepatitis C infection following treatment are desperately ill. Researchers at the 2015 International Liver Congress reported that a fixed dose combination of ledipasvir/sofosbuvir given in combination with ribavirin helped many of these patients, according to the results from the SOLAR 2 trial.
An estimated 11,000 attendees from 105 countries are converging in Vienna, Austria for the 50th International Liver Congress, hosted by the European Association for the Study of the Liver (ILC/EASL). Some 200 journalists -- including a team from MD Magazine--are on hand to report the news. Eagerly awaited trials include those of two drugs that show promise for treating a common liver disease associated with obesity, known medically as non-alcoholic steatohepatitis (NASH) and its precursor non-alcoholic fatty liver disease (NAFLD).